Progressive supranuclear palsy (PSP) is a primary tauopathy associated with a heterogeneous spectrum of clinicopathological features and, consequently, different clinical subgroups have been designated as PSP variants. Many neuroimaging studies have proposed different biomarkers for PSP, including magnetic resonance imaging (MRI), Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), and presynaptic dopaminergic imaging. The PSP clinical diagnostic criteria of the Movement Disorder Society currently include these imaging biomarkers as supportive feature. In this chapter we describe two illustrative cases of the most frequent PSP variant, Richardson syndrome, and the parkinsonian variant.